Credit Suisse’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Credit Suisse’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-838	Closed	-$1K	–	4461
2022 Q2	$1K	Buy	+838	New	+$1.68K	﹤0.01%	3861

Other funds holding CYAD

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Credit Suisse's CYAD Position: Q3 2022 in Review

Credit Suisse sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q3 2022, closing a stake of 838 shares — an estimated $1K sold.

Credit Suisse first reported a position in CYAD in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 8 funds tracked by Wall St. Rank hold CYAD as of Q3 2022.

Credit Suisse reported no remaining Celyad Oncology SA American Depositary Shares position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 838 Celyad Oncology SA American Depositary Shares shares in Q3 2022, an estimated $1K.
Credit Suisse first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2022 and held it in 1 quarter.
Credit Suisse's Celyad Oncology SA American Depositary Shares position peaked at $1K in Q2 2022.
8 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.